Physician profile
Chloe Ray
NPI 1568927697
$1,697.46
in general payments reported to CMS, 2019-2025
13 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $313 · 2023: $562 · 2024: $335 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Education: $91.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.73 |
| Education | $91.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $514.31 | 2022-2025 | Talvey, Tecvayli, Darzalex |
| Celgene Corporation | $266.21 | 2021-2023 | Pomalyst |
| Genzyme Corporation | $226.32 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $147.74 | 2023-2025 | Xpovio |
| Sanofi-Aventis U.S. LLC | $133.14 | 2023-2024 | |
| Janssen Research & Development, LLC | $104.03 | 2023 | |
| Amgen INC. | $75.87 | 2021-2023 | Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $66.56 | 2021-2022 | |
| Pfizer INC. | $62.01 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $27.97 | 2025 | Clonoseq |
| Legend Biotech USA INC. | $27.17 | 2025 | Carvykti |
| Kite Pharma, INC. | $23.86 | 2024 | Yescarta |
| Genentech USA, INC. | $22.27 | 2025 | Gazyva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.